benign

Alfuzosin (SL 77499) is an orally available, competitive α1-adrenoceptor antagonist.Alfuzosin induces smooth muscle relaxation in the bladder neck and prostate.Alfuzosin has been used to study benign prostatic hypertrophy, lower urinary tract symptoms (LUTS), and ejaculatory dysfunction (EjD).

Dapoxetine hydrochloride (LY-210448 hydrochloride) is a selectivity short-acting serotonin reuptake inhibitor, used for the therapy of premature ejaculation.

Taprizosin（UK-338003） is a selective and orally active α1-adrenoceptor antagonist for vasodilatation in the treatment of benign prostatic hyperplasia.

Gestonorone Capronate  is a progesterone used to treat benign prostatic hyperplasia and endometrial cancer.

Tamsolusin Hydrochloride (YM 12617) is a highly selective alpha-1A adrenergic receptor antagonist used in the treatment of benign prostatic hypertrophy.

Xinidamine (BRN 0891979) has antitumor activity and can be used to study benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia .Xinidamine inhibits the proliferation of PWR-1E cells with an IC50 of 4 μM.

Terazosin hydrochloride (Hytrin) , a selective alpha1-antagonist, can treat the benign prostatic hyperplasia (BPH). It also can lower blood pressure, so it is a drug of choice for patients with prostate enlargement and hypertension. It works on the smooth muscle of the bladder and the blood vessel walls by blocking the function of adrenaline.

Dutasteride (GI 198745) is a 5-alpha-reductase inhibitor that inhibits both type-1 and type2 isoforms of the enzyme and is used to treat benign prostatic hyperplasia.

TF-505, a steroid 5α-reductase inhibitor, is used potentially for the treatment of benign prostatic hyperplasia.

C16 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from C16 lactosylceramide . C16 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease. C16 globotriaosylceramide is also upregulated in plasma of patients with ovarian carcinoma compared to those with benign ovarian tumors or uterine fibroids.

Dapoxetine (Dapoxetina) is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation.

Tinlorafenib (PF-07284890) (compound 10) is an orally active, central nervous system (CNS)-permeable BRAF kinase inhibitor that acts on BRAFV600E (IC50: 4.25 nM) and V600K (IC50: 2.7 nM). Tinlorafenib can be used in the study of BRAF-associated malignant and benign tumours of the central nervous system and extracranial malignancies.

Fiduxosin hydrochloride is an alpha 1a-adrenoceptor antagonist that may be useful in the treatment of Benign Prostatic Hyperplasia.

Pikamilone Sodium is a prodrug of GABA used for therapy of neurogenic bladder in spinal and benign prostatic hyperplasia.

L-771688 is an α1A-adrenoceptor antagonist potentially for the treatment of benign prostatic hyperplasia.

Fexapotide (NX-1207 free acid) selectively induces apoptosis, effectively reducing prostate volume at the cellular level. This compound is applicable in the research of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) [1] [2] [3].

Phenylethyl isothiocyanate (JC5411) is an HDAC inhibitor. It potentially for the treatment of benign prostatic hypertrophy.

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

ONO-0300302 is a slow tight binding LPA1 antagonist (IC50: 0.16 nM) used to treat Benign Prostatic Hyperplasia. ONO-0300302 inhibits significantly an LPA-induced increase of intraurethral pressure (IUP) in rat (3 mg/kg, p.o.) and dog (1 mg/kg, p.o.) over

Alfuzosin hydrochloride (Alfuzosin HCl) is an α1 adrenergic receptor antagonist. It applies to treat benign prostatic hyperplasia (BPH).

Doxazosin (UK 33274) is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms.

Tamsulosin ((R)-(-)-YM12617 free base) is an alpha1A adrenergic receptor antagonist for the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin is used to treat difficulty urinating, a common symptom of an enlarged prostate. Tansulosin and other drugs called alpha blockers work by relaxing the neck muscles of the bladder and muscle fibers in the prostate itself, making it easier to urinate.

Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC 50 of 4.2 nM for type II 5α-reductase. The affinity of Finasteride acetate for type II 5α-reductase enzyme was approximately 100-fold higher than that for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia [1] [2] [3].

Grandifloroside shows good antioxidative and potent anti-inflammatory activities, it also exhibits potent inhibitory activity against TNF-α and 5α-reductase, suggests that it might be developed as a source of potent anti-oxidative and anti-inflammatory ag

Bifluranol (BX341) has anti-androgenic activity and has shown significant anti-prostatic activity in in vivo studies for the treatment of benign prostatic hyperplasia (BPH).

Fiduxosin is a selective and potent α1-adrenoceptor antagonist with inhibitory effects on α1a-adrenoceptor, α1b-adrenoceptor and α1d-adrenoceptor, with Ki values of 0.160 nM, 24.9 nM and 0.920 nM, respectively. Fiduxosin can be used for the treatment of benign prostatic hyperplasia.

Fexapotide triflutate is a caspase and TNF signaling pathway activator used to treat benign prostatic hyperplasia (BPH).

H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) can be used as the biomarker to distinguish benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH is an orally active Angiotensin-converting enzyme inhibitor with the 48% inhibiton rate at 50 μM. H-Tyr-Phe-OH shows xanthine oxidase inhibitory activity(uric acid lowering) that acts as regulator of IL-8 production in neutrophil-like cells [1] [2] [3] [4].

Sitostenone has antioxidation activity. Stigmasta-4-en-3-one(Sitostenone) can be used for the treatment of androgen-dependent diseases, especially for the treatment of benign prostatic hyperplasia.

Lysinenorleucine s a Lysine and hydroxylysine derivatives that can be used for the treatment of malignant and benign tumors.

Terazosin hydrochloride dihydrate (Heitrin dihydrate) is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).

Terazosin-d8 is a deuterated compound of Terazosin. Terazosin has a CAS number of 63590-64-7. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment [1] [2] [3].

Ganoderol B is a potent β ±-glucosidase and angiotensin-converting enzyme inhibitor, with an IC(50) of β ±-glucosidase is 119.8 uM. It may be useful in prostate cancer and benign prostatic hyperplasia (BPH) therapy through suppressing the function of andr

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

GYKI-16084 is a postsynaptic alpha2 receptor blocker with potential efficacy in the treatment of benign prostatic hyperplasia.

L-771688 (SNAP 6383) is a novel potent and selective α1A-adrenoceptor antagonist with a Ki value of 0.43±0.02 nM.L-771688 KE is used for the treatment of benign prostatic hyperplasia.

Cichoriin is a photosensitive compound, it could be used as herbal photosensitizing agent in treating benign breast tumor in rats.

Monoethyl phthalate is the major metabolite of diethyl phthalate in urine and is a potential indicator for the detection of thyroid cancer and benign nodules.

Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3].

Silodosin (KAD 3213) is an alpha-Adrenergic Blocker. The mechanism of action of silodosin is as an Adrenergic alpha-Antagonist.

(R)-Terazosin is an active R-enantiomer of Terazosin. (R)-Terazosin is a potent antagonist of α1-adrenoceptor (α1a, α1b and α1d-adrenoceptor with Ki values of 6.51 nM, 1.01 nM and 1.97 nM, respectively).

(S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity antagonist of α-adrenoceptor(α1a, α1b and α1d-adrenoceptor with Ki values of 3.91 nM, 0.79 nM and 1.16 nM, respectively).